

## APC/Cyanine7 anti-mouse CD45 Antibody

<b>Catalog# / Size</b>	103115 / 25 µg 103116 / 100 µg
<b>Clone</b>	30-F11
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T200, Ly-5, LCA
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.  Additional reported applications (for relevant formats) include: immunoprecipitation <sup>3</sup> , complement-dependent cytotoxicity <sup>1,5</sup> , immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections) <sup>4,6</sup> , Western blotting <sup>7</sup> , and spatial biology (IBEX) <sup>10,11</sup> . The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).
<b>Additional Product Notes</b>	BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact <a href="#">Technical Service</a> if you have any questions.
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Podd BS, <i>et al.</i> 2006. <i>J. Immunol.</i> 176:6532. (FC, CMCD) <a href="#">PubMed</a></li> <li>2. Haynes NM, <i>et al.</i> 2007. <i>J. Immunol.</i> 179:5099. (FC)</li> <li>3. Ledbetter JA, <i>et al.</i> 1979. <i>Immunol. Rev.</i> 47:63. (IP)</li> <li>4. Simon DI, <i>et al.</i> 2000. <i>J. Clin. Invest.</i> 105:293. (IHC)</li> <li>5. Seaman WE. 1983. <i>J. Immunol.</i> 130:1713. (CMCD)</li> </ol>

6. Cornet A, *et al.* 2001. *P. Natl. Acad. Sci. USA* 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. *J. Biol. Chem.* 273:30680. (WB) [PubMed](#)
8. Liu F, *et al.* 2012. *Blood.* 119:3295. [PubMed](#)
9. Pelletier AN, *et al.* 2012. *J. Immunol.* 188:5561. [PubMed](#)
10. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
11. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Chang YS, *et al.* 2020. *Int J Mol Sci.* 21:00. [PubMed](#)
2. Naito H, *et al.* 2020. *Nature Protocols.* 15(3):1066-1081. [PubMed](#)
3. Xing J, *et al.* 2021. *Cell Reports.* 35(12):109205. [PubMed](#)
4. Cignarella F *et al.* 2018. *Cell metabolism.* 27(6):1222-1235. [PubMed](#)
5. Contijoch EJ *et al.* 2019. *eLife.* 8 pii: e40553. [PubMed](#)
6. Wu J *et al.* 2017. *Immunity.* 47(6):1114-1128. [PubMed](#)
7. Komuczki J, *et al.* 2019. *Immunity.* 50:1289. [PubMed](#)
8. Wang X, *et al.* 2019. *Cell Res.* 29:787. [PubMed](#)
9. Yu X, *et al.* 2020. *Nat Commun.* 11:1110. [PubMed](#)
10. Heindl S, *et al.* 2021. *J Exp Med.* 218:. [PubMed](#)
11. Stefkovich M, *et al.* 2021. *Mol Metab.* 54:101357. [PubMed](#)
12. Wang Q, *et al.* 2020. *Radiat Environ Biophys.* 59:89. [PubMed](#)
13. Kim MY, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
14. De Vries LCS, *et al.* 2021. *J Crohns Colitis.* 15:617. [PubMed](#)
15. Bernasconi R, *et al.* 2021. *EMBO Mol Med.* :e14392. [PubMed](#)
16. Miranda K, *et al.* 2022. *iScience.* 25:104994. [PubMed](#)
17. Da Mesquita S, *et al.* 2021. *Nature.* 593:255. [PubMed](#)
18. Furrer R, *et al.* 2021. *Sci Adv.* 7:eabi4852. [PubMed](#)
19. Ren D, *et al.* 2022. *STAR Protoc.* 3:101217. [PubMed](#)
20. Kim JS, *et al.* 2020. *Immunity.* 54(1):176-190.e7. [PubMed](#)
21. Rosenkranz SC, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
22. Kokona D, *et al.* 2016. *Exp Eye Res.* S0014-4835(16)30499-7. [PubMed](#)
23. Page N, *et al.* 2018. *Immunity.* 48:937. [PubMed](#)
24. Frisbee AL, *et al.* 2019. *Nat Commun.* 10:2712. [PubMed](#)
25. Ajina R, *et al.* 2019. *Oncoimmunology.* 8:e1577127. [PubMed](#)
26. Groza D, *et al.* 2018. *Oncoimmunology.* 7:e1424676. [PubMed](#)
27. Iwamoto H *et al.* 2018. *Cell metabolism.* 28(1):104-117. [PubMed](#)
28. Lyons J, *et al.* 2018. *PLoS Biol.* 16:e2002417. [PubMed](#)
29. Schloss MJ, *et al.* 2022. *Nat Immunol.* 23:605. [PubMed](#)
30. Wu SY, *et al.* 2022. *Mol Cancer.* 21:84. [PubMed](#)
31. Efferm M, *et al.* 2022. *STAR Protoc.* 3:101038. [PubMed](#)
32. Jiang Q, *et al.* 2022. *Theranostics.* 12:59. [PubMed](#)
33. Tripathi H, *et al.* 2020. *J Mol Cell Cardiol.* 149:95. [PubMed](#)
34. Fan L, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
35. Urban SK, *et al.* 2020. *Liver Int.* 40:3103. [PubMed](#)
36. Radovanovic I, *et al.* 2014. *J Immunol.* 193:1290. [PubMed](#)
37. Evans H, *et al.* 2015. *J Immunol.* 195: 2973 - 2984. [PubMed](#)
38. Cardona S, *et al.* 2015. *ASN Neuro.* 7: 1759091415608204. [PubMed](#)
39. Mogilenko DA, *et al.* 2020. *Immunity.* 54(1):99-115.e12. [PubMed](#)
40. Uzhachenko RV, *et al.* 2021. *Cell Reports.* 35(1):108944. [PubMed](#)
41. Ebnetter A, *et al.* 2017. *Transl Vis Sci Technol.* 10.1167/tvst.6.2.10. [PubMed](#)
42. Kim TJ, *et al.* 2019. *Nat Commun.* 10:3258. [PubMed](#)
43. Saleh MM, *et al.* 2019. *Cell Host Microbe.* 25:756. [PubMed](#)
44. Blecher-Gonen R, *et al.* 2019. *Cell Syst.* 8:109. [PubMed](#)
45. Kashyap AS, *et al.* 2019. *Cell Rep.* 28:3367. [PubMed](#)
46. Pluchino N, *et al.* 2020. *J Cell Mol Med.* 24:2464. [PubMed](#)
47. Chou YJ, *et al.* 2020. *Sci Rep.* 10:8422. [PubMed](#)
48. Rodriguez-Garcia A, *et al.* 2021. *Nat Commun.* 12:877. [PubMed](#)
49. Van Den Eeckhout B, *et al.* 2020. *NPJ Vaccines.* 5:64. [PubMed](#)
50. Baram T, *et al.* 2021. *Cells.* 10:. [PubMed](#)
51. Pan Y, *et al.* 2021. *Front Cell Neurosci.* 15:664312. [PubMed](#)
52. Yang C, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
53. Luo R, *et al.* 2021. *Theranostics.* 11:117. [PubMed](#)
54. Adrover JM, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
55. Steubing RD, *et al.* 2022. *Brain Behav Immun Health.* 24:100493. [PubMed](#)
56. Lu H, *et al.* 2021. *Autophagy.* 17:2511. [PubMed](#)
57. Kawashima N, *et al.* 2022. *Nat Commun.* 13:1624. [PubMed](#)
58. Zhu S, *et al.* 2022. *Front Pharmacol.* 13:996635. [PubMed](#)
59. Palacios LM, *et al.* 2022. *Biology (Basel).* 11:. [PubMed](#)
60. Forte E, *et al.* 2020. *J Cell Mol Med.* . [PubMed](#)
61. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
62. Han Y, *et al.* 2020. *Nat Commun.* 11:1776. [PubMed](#)
63. Lechner AJ *et al.* 2017. *Cell stem cell.* 21(1):120-134. [PubMed](#)
64. Haertel E, *et al.* 2018. *Eur J Immunol.* 48:1001. [PubMed](#)
65. Tordesillas L, *et al.* 2018. *Nat Commun.* 9:5238. [PubMed](#)
66. Yuzhu Hou *et al.* 2018. *Immunity.* 49(3):490-503. [PubMed](#)
67. Bowers E, *et al.* 2018. *Nat Med.* 24:95. [PubMed](#)
68. Zhou X, *et al.* 2022. *Front Pharmacol.* 13:887263. [PubMed](#)
69. Biswas S, *et al.* 2021. *Nature.* 591:464. [PubMed](#)
70. Khandelwal P, *et al.* 2013. *PLoS One.* 8:64193. [PubMed](#)
71. Shibata K, *et al.* 2014. *J Immunol.* 192:2210. [PubMed](#)

72. Mantia-Smaldone G, *et al.* 2014. *Gynecol Oncol.* 133:584. [PubMed](#)
73. Rybalko V, *et al.* 2015. *PLoS One.* 10: 0145550. [PubMed](#)
74. AR P, *et al.* 2016. *Circ Res.* 118: 400-409. [PubMed](#)
75. Zhu B, *et al.* 2021. *Immunity.* 54(6):1200-1218.e9. [PubMed](#)
76. Zhao B, *et al.* 2021. *Cell Reports.* 36(3):109401. [PubMed](#)
77. Jtte BB, *et al.* 2021. *iScience.* 24(8):102833. [PubMed](#)
78. Uroda T, *et al.* 2020. *Nat Protoc.* 15:2107. [PubMed](#)
79. Ganeshan K *et al.* 2019. *Cell.* 177(2):399-413 . [PubMed](#)
80. Wiley CD, *et al.* 2019. *JCI Insight.* 4:e130056. [PubMed](#)
81. Krasteva G, *et al.* 2011. *Proc Natl Acad Sci U S A.* 108:9478. [PubMed](#)
82. Yoon Y, *et al.* 2021. *Cancers (Basel).* 13: . [PubMed](#)
83. Shi S, *et al.* 2020. *Clin Cancer Res.* 26:5990. [PubMed](#)
84. Mathur S, *et al.* 2021. *JCI Insight.* 6: . [PubMed](#)
85. Armaka M, *et al.* 2022. *Genome Med.* 14:78. [PubMed](#)
86. Yang W, *et al.* 2020. *Mucosal Immunol.* 13:788. [PubMed](#)
87. Jung BG, *et al.* 2022. *PLoS Pathog.* 18:e1010454. [PubMed](#)
88. Dieterich LC, *et al.* 2019. *International Journal of Cancer.* 145(10):2804-2815. [PubMed](#)
89. Marangoni F, *et al.* 2021. *Cell.* . [PubMed](#)
90. Wang LT, *et al.* 2021. *STAR Protocols.* 2(1):100337. [PubMed](#)
91. Fachi JL, *et al.* 2020. *J Exp Med.* 217:00:00. [PubMed](#)
92. Chew W, *et al.* 2016. *Nat Methods.* 13: 868-874. [PubMed](#)
93. Cordeiro O, *et al.* 2016. *PLoS One.* 11: 0151848. [PubMed](#)
94. Zhang C, *et al.* 2020. *Cell Metabolism.* 31(1):148-161.e5.. [PubMed](#)
95. Huang B, *et al.* 2020. *Cell.* 179(5):1160-1176.e24.. [PubMed](#)
96. Ning F, *et al.* 2019. *J Exp Med.* 216:1396. [PubMed](#)
97. Higashi AY, *et al.* 2019. *J Am Soc Nephrol.* 30:80. [PubMed](#)
98. Lyons J, *et al.* 2018. *Sci Signal.* 11. [PubMed](#)
99. Evans R, *et al.* 2019. *Cell Rep.* 27:1967. [PubMed](#)
100. Hammond TR, *et al.* 2019. *Immunity.* 50:253. [PubMed](#)
101. Schönfeld M, *et al.* 2021. *Alcohol Clin Exp Res.* 45:1980. [PubMed](#)
102. Bhattacharjee A, *et al.* 2021. *Mol Neurodegener.* 16:19. [PubMed](#)
103. Bagayoko S, *et al.* 2021. *PLoS Pathog.* 17:e1009927. [PubMed](#)
104. Liu M, *et al.* 2020. *Cell Rep.* 32:107990. [PubMed](#)
105. Jeljelii M, *et al.* 2020. *Cell Rep.* 33:108325. [PubMed](#)
106. Montel-Hagen A, *et al.* 2020. *Cell Rep.* 33:108320. [PubMed](#)
107. Chi Z, *et al.* 2020. *Molecular Cell.* 80(1):43-58.e7. [PubMed](#)
108. Koliaraki V *et al.* 2019. *Cell reports.* 26(3):536-545 . [PubMed](#)
109. Commerford CD *et al.* 2018. *Cell reports.* . [PubMed](#)
110. Zeng J, *et al.* 2019. *Cell Rep.* 27:549. [PubMed](#)
111. Yousef H, *et al.* 2018. *Bio Protoc.* 8:22. [PubMed](#)
112. Willingham SB, *et al.* 2018. *Cancer Immunol Res.* 6:1136. [PubMed](#)
113. Weiner AI, *et al.* 2019. *NPJ Regen Med.* 4:17. [PubMed](#)
114. Davidson S, *et al.* 2020. *Cell Reports.* 31(7):107628. [PubMed](#)
115. Qi X, *et al.* 2019. *Nat Med.* 25:1225. [PubMed](#)
116. Liu H, *et al.* 2020. *Cancer Cell.* 37(3):324-339. [PubMed](#)
117. Hillel-Karniel C, *et al.* 2020. *Cell Reports.* 30(3):807-819.e4.. [PubMed](#)
118. Gui J, *et al.* 2020. *Nat Cancer.* 1:603. [PubMed](#)
119. Donlan AN, *et al.* 2020. *Anaerobe.* 66:102275. [PubMed](#)
120. Uher O, *et al.* 2021. *Cancers (Basel).* 13: . [PubMed](#)
121. Friei J, *et al.* 2021. *Immunity.* 54(5):1002-1021.e10. [PubMed](#)
122. Alshetaiwi H, *et al.* 2020. *Sci Immunol.* 5:00. [PubMed](#)
123. Zhang X, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
124. Ji B, *et al.* 2016. *Cell Death Differ.* 23:759-75. [PubMed](#)
125. Utz B, *et al.* 2020. *Sci Rep.* 10:18733. [PubMed](#)
126. Chun E, *et al.* 2020. *Immunity.* 51(5):871-884.e6.. [PubMed](#)
127. Bahar Halpern K, *et al.* 2020. *Nat Commun.* 11:1936. [PubMed](#)
128. Soldevilla MM, *et al.* 2019. *Mol Ther.* 27:1878. [PubMed](#)
129. Hurrell BP, *et al.* 2019. *Cell Rep.* 29:4509. [PubMed](#)
130. Li Y, *et al.* 2019. *Sci Rep.* 9:6932. [PubMed](#)
131. Mifflin L, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118: . [PubMed](#)
132. Stewart JM, *et al.* 2020. *ACS Biomater Sci Eng.* 6:5941. [PubMed](#)
133. Gao H, *et al.* 2021. *Cells.* 10: . [PubMed](#)
134. Korangath P, *et al.* 2020. *Bio Protoc.* 10:e3822. [PubMed](#)
135. Ajina R, *et al.* 2021. *Cancer Immunol Res.* 9:386. [PubMed](#)
136. Veremeyko T, *et al.* 2012. *J Vis Exp.* 65: 4097. [PubMed](#)
137. Fu H, *et al.* 2020. *Front Immunol.* 11:595813. [PubMed](#)
138. Oladiran O, *et al.* 2021. *J Neuroinflammation.* 77:18. [PubMed](#)
139. Ayaub E, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-13511-z. [PubMed](#)
140. Peralta Ramos JM, *et al.* 2017. *Front Immunol.* 1.490277778. [PubMed](#)
141. Halpern KB, *et al.* 2018. *Nat Biotechnol.* 36:962. [PubMed](#)
142. Alikhanyan K, *et al.* 2021. *Cancers (Basel).* 13: . [PubMed](#)
143. Du Y, *et al.* 2022. *Nat Commun.* 13:231. [PubMed](#)
144. Ali M, *et al.* 2022. *JCI Insight.* 7: . [PubMed](#)
145. Formaglio P, *et al.* 2021. *Immunity.* 54:2724. [PubMed](#)
146. Cho YK, *et al.* 2022. *Nat Commun.* 13:4084. [PubMed](#)
147. Ghandhi SA, *et al.* 2022. *Sci Rep.* 12:14124. [PubMed](#)
148. Guo P, *et al.* 2021. *J Immunol.* 207:408. [PubMed](#)
149. Toubal A, *et al.* 2020. *Nat Commun.* 3755:11. [PubMed](#)
150. McFarland AP, *et al.* 2021. *Immunity.* 54(6):1320-1337.e4. [PubMed](#)
151. Tacconi C, *et al.* 2021. *Cell Reports.* 35(2):108993. [PubMed](#)

152. Dieterich LC, *et al.* 2020. *Angiogenesis*. 1:24375. [PubMed](#)
153. Martina M, *et al.* 2014. *J Vis Exp*. 87: 51192. [PubMed](#)
154. Frodermann V, *et al.* 2019. *Nat Med*. 25:1761. [PubMed](#)
155. Chauveau A, *et al.* 2020. *Immunity*. 52:794. [PubMed](#)
156. Haikala HM, *et al.* 2019. *Nat Commun*. 10:620. [PubMed](#)
157. Hu Y, *et al.* 2022. *J Nanobiotechnology*. 20:417. [PubMed](#)
158. Neuhöfer P, *et al.* 2021. *Nature*. 597:715. [PubMed](#)
159. Yang J, *et al.* 2022. *Microbiome*. 10:149. [PubMed](#)
160. Hum NR, *et al.* 2022. *Front Oncol*. 12:928474. [PubMed](#)
161. Bergin SM, *et al.* 2021. *Brain Behav Immun*. 95:477. [PubMed](#)
162. Selvaraj UM, *et al.* 2021. *Brain Behav Immun*. 95:502. [PubMed](#)
163. Ying T, *et al.* 2021. *Am J Physiol Endocrinol Metab*. 320:E1148. [PubMed](#)
164. Chen Y, *et al.* 2022. *Front Immunol*. 13:835690. [PubMed](#)
165. Momin N, *et al.* 2022. *Nat Commun*. 13:109. [PubMed](#)
166. Uddin MJ, *et al.* 2022. *Mucosal Immunol*. 15:165. [PubMed](#)
167. Pilonas KA, *et al.* 2020. *Cancer Immunol Res*. 8:1054. [PubMed](#)
168. Abramowski P, *et al.* 2014. *J Neuroimmunol*. 274:111. [PubMed](#)
169. Hoeksema M, *et al.* 2015. *J Immunol*. 194:3909. [PubMed](#)
170. Dhanwani R, *et al.* 2020. *Sci Adv*. 6:eaba3688. [PubMed](#)
171. Tripathi H, *et al.* 2020. *Stem Cell Rev Rep*. 0.953472222. [PubMed](#)
172. Cardenas JJ, *et al.* 2020. *Methods Enzymol*. 415:631. [PubMed](#)
173. Alikhanyan K, *et al.* 2020. *Immun Inflamm Dis*. 8:181. [PubMed](#)
174. Cheng Y, *et al.* 2019. *Clin Cancer Res*. 25:2621. [PubMed](#)
175. Shannon JP, *et al.* 2021. *STAR Protoc*. 2:100790. [PubMed](#)
176. Yang Y, *et al.* 2022. *Elife*. 11:. [PubMed](#)
177. Li H, *et al.* 2021. *Adv Sci (Weinh)*. 2001596:8. [PubMed](#)
178. Shannon JP, *et al.* 2021. *Immunity*. 54(2):276-290.e5. [PubMed](#)
179. Alonso-Herranz L, *et al.* 2020. *Elife*. 9:00. [PubMed](#)
180. Gierut J, *et al.* 2015. *Stem Cell Res*. 15: 165-171. [PubMed](#)
181. Seki T, *et al.* 2015. *J Biochem*. 158: 485 - 495. [PubMed](#)
182. Haka A, *et al.* 2012. *PLoS One*. 7:e44823. [PubMed](#)
183. Kaya B, *et al.* 2020. *Cell Reports*. 32(5):107979. [PubMed](#)
184. Sztwiertnia I, *et al.* 2020. *PLoS One*. 15:e0233789. [PubMed](#)
185. Sydney Lavoie *et al.* 2019. *eLife*. 8 pii: e39982. [PubMed](#)
186. Wang R, *et al.* 2022. *Front Immunol*. 13:947756. [PubMed](#)
187. Becker W, *et al.* 2021. *J Crohns Colitis*. 15:1032. [PubMed](#)
188. Galle-Treger L, *et al.* 2020. *J Allergy Clin Immunol*. 145:502. [PubMed](#)
189. Maulloo CD, *et al.* 2021. *Front Immunol*. 12:714842. [PubMed](#)
190. Clement CC, *et al.* 2021. *Nat Commun*. 12:4447. [PubMed](#)
191. Henrich IC, *et al.* 2021. *Cancer Res*. 81:2171. [PubMed](#)
192. Huetter J, *et al.* 2020. *Cancer Immunol Res*. 0.954861111. [PubMed](#)
193. Favuzzi E, *et al.* 2021. *Cell*. 184(15):4048-4063.e32. [PubMed](#)
194. DiToro D, *et al.* 2020. *Immunity*. 650:52. [PubMed](#)
195. Veremeyko T, *et al.* 2019. *J Neurosci Res*. 97:162. [PubMed](#)
196. Galle-Treger L, *et al.* 2019. *Nat Commun*. 10:713. [PubMed](#)
197. Kim MY, *et al.* 2018. *Cell*. 173:1439. [PubMed](#)
198. Camara A, *et al.* 2019. *Immunity*. 50:1467. [PubMed](#)
199. Michaelis KA, *et al.* 2019. *Brain Behav Immun*. 82:338. [PubMed](#)
200. Wuggenig P, *et al.* 2020. *Commun Biol*. 3:130. [PubMed](#)
201. Xu Q, *et al.* 2021. *Theranostics*. 11:1937. [PubMed](#)
202. Yu H, *et al.* 2021. *Front Oncol*. 11:736882. [PubMed](#)
203. Zhang R, *et al.* 2022. *Front Pharmacol*. 13:870848. [PubMed](#)
204. Yu W, *et al.* 2022. *Nat Commun*. 13:3544. [PubMed](#)
205. Li D, *et al.* 2022. *Emerg Microbes Infect*. 11:2248. [PubMed](#)
206. Ou YC, *et al.* 2020. *ACS Nano*. 1.035416667. [PubMed](#)
207. Hirata SI, *et al.* 2020. *Allergy*. 75:1939. [PubMed](#)
208. Zelco A, *et al.* 2020. *Front Cell Neurosci*. 0.75625. [PubMed](#)
209. Wang LT, *et al.* 2020. *Cell Rep*. 32:108188. [PubMed](#)
210. Hadas R, *et al.* 2020. *JCI Insight*. 5:00. [PubMed](#)
211. Stock M, *et al.* 2015. *Osteoarthritis Cartilage*. 23: 1221-1225. [PubMed](#)
212. Draper D, *et al.* 2012. *J Immunol*. 188:5327. [PubMed](#)
213. Hohsfield LA, *et al.* 2020. *J Neuroinflammation*. 0.902083333. [PubMed](#)
214. Godwin MS, *et al.* 2019. *JCI Insight*. 4:e126070. [PubMed](#)
215. Yuan X, *et al.* 2017. *Elife*. 6:e29540. [PubMed](#)
216. Xueyang Yu *et al.* 2017. *Immunity*. 47(5):903-912. [PubMed](#)
217. Selvaraj UM *et al.* 2018. *Endocrinology*. 159(11):3848-3859. [PubMed](#)
218. Pinho-Ribeiro FA, *et al.* 2018. *Cell*. 173:1083. [PubMed](#)
219. Duarte D, *et al.* 2018. *Cell Stem Cell*. 22:64. [PubMed](#)
220. Hsu M, *et al.* 2022. *Nat Immunol*. 23:581. [PubMed](#)
221. Sakamoto K, *et al.* 2021. *Immunity*. 54:2321. [PubMed](#)
222. Takaku S, *et al.* 2022. *Evid Based Complement Alternat Med*. 2022:6122955. [PubMed](#)
223. Wang X, *et al.* 2022. *Front Immunol*. 13:864984. [PubMed](#)
224. Galani IE, *et al.* 2022. *STAR Protoc*. 3:101151. [PubMed](#)
225. Abdelfattah N, *et al.* 2022. *Nat Commun*. 13:767. [PubMed](#)
226. Martina M, *et al.* 2016. *J Am Soc Nephrol*. 27: 1113-1123. [PubMed](#)
227. Da Mesquita S, *et al.* 2021. *Science Advances*. 7(21):. [PubMed](#)
228. Wakabayashi T *et al.* 2018. *Cell stem cell*. 22(3):384-397. [PubMed](#)
229. Kaiser T, *et al.* 2019. *Eneuro*. 6. [PubMed](#)
230. El Agha E, *et al.* 2017. *Cell Stem Cell*. 1.014583333. [PubMed](#)
231. Yousef H, *et al.* 2019. *Nat Med*. 25:988. [PubMed](#)



232. Ben-Moshe S, *et al.* 2019. *Nat Metab.* 1:899. [PubMed](#)
233. Bhatt D, *et al.* 2021. *J Exp Med.* 218:. [PubMed](#)
234. Lu Z, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
235. Luo M, *et al.* 2021. *J Immunol.* 207:1683. [PubMed](#)
236. Klein S, *et al.* 2016. *J Cell Sci.* 129: 2573 - 2585. [PubMed](#)
237. Yu L, *et al.* 2020. *Nat Commun.* 2.045833333. [PubMed](#)
238. Liu X, *et al.* 2019. *Mol Cancer Ther.* 18:706. [PubMed](#)
239. Ji L *et al.* 2019. *Immunity.* 51(2):272-284 . [PubMed](#)
240. Jiang P, *et al.* 2018. *Nat Med.* 24:1550. [PubMed](#)
241. Wang X, *et al.* 2018. *Nat Commun.* 9:551. [PubMed](#)
242. Li N, *et al.* 2022. *Nat Commun.* 13:7281. [PubMed](#)
243. Pedicone C, *et al.* 2022. *iScience.* 25:104170. [PubMed](#)
244. Godwin MS, *et al.* 2021. *Am J Physiol Lung Cell Mol Physiol.* 320:L393. [PubMed](#)
245. Reda M, *et al.* 2022. *Nat Commun.* 13:4261. [PubMed](#)
246. Li Y, *et al.* 2022. *STAR Protoc.* 3:101364. [PubMed](#)
247. Leary N, *et al.* 2022. *J Extracell Vesicles.* 11:e12197. [PubMed](#)
248. Milich LM, *et al.* 2021. *J Exp Med.* 218:. [PubMed](#)
249. Kline JM, *et al.* 2021. *J Biol Chem.* :100373. [PubMed](#)
250. Kiss M, *et al.* 2020. *Cancer Immunol Res.* 9:309. [PubMed](#)
251. Starikova E, *et al.* 2021. *Front Pharmacol.* 12:667572. [PubMed](#)
252. Yoldi G, *et al.* 2016. *Cancer Res.* 76: 5857 - 5869. [PubMed](#)
253. Ling Y, *et al.* 2016. *Pharmacol Res.* S1043-6618(16)31329-9. [PubMed](#)
254. Blaszczak AM, *et al.* 2020. *Immunometabolism.* 2:00. [PubMed](#)
255. Lu C, *et al.* 2020. *Cancer Cell.* 39(1):96-108.e6. [PubMed](#)
256. Yang C, *et al.* 2020. *Cell Host Microbe.* 467:27. [PubMed](#)
257. Armaka M, *et al.* 2018. *Nat Commun.* 9:618. [PubMed](#)
258. Lang JF *et al.* 2019. *Nat Commun.* 10(1):3415 . [PubMed](#)
259. Theurich S *et al.* 2017. *Cell metabolism.* 26(1):171-184 . [PubMed](#)
260. Martin A, *et al.* 2018. *Oncotarget.* 9:28364. [PubMed](#)
261. Zhao Y, *et al.* 2020. *Front Immunol.* 2.572222222. [PubMed](#)
262. Yoshida H, *et al.* 2019. *Cell.* 176:897. [PubMed](#)
263. Ireland L, *et al.* 2020. *Front Immunol.* 11:297. [PubMed](#)
264. Gago-Lopez N, *et al.* 2019. *EMBO Mol Med.* 11:e10697. [PubMed](#)
265. Van Den Eeckhout B, *et al.* 2020. *NPJ Vaccines.* 0.252777778. [PubMed](#)
266. Uluçkan ö, *et al.* 2020. *Cell Reports.* 29(4):844-859.e3.. [PubMed](#)
267. Morein D, *et al.* 2021. *Cells.* 10: . [PubMed](#)
268. Yan C, *et al.* 2022. *NPJ Precis Oncol.* 6:6. [PubMed](#)
269. Phansalkar R, *et al.* 2021. *Elife.* 10:. [PubMed](#)
270. Kim S, *et al.* 2022. *Cancers (Basel).* 14:. [PubMed](#)
271. Liu SS, *et al.* 2021. *Immunity.* .: [PubMed](#)
272. Ukidve A, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:17727. [PubMed](#)
273. E O'Koren, R Mathew, D Saban 2016. *Sci Rep.* 6:20636. [PubMed](#)
274. Rosnagl S, *et al.* 2016. *PLoS Biol.* 14: 1002562. [PubMed](#)
275. Pelly V, *et al.* 2016. *Mucosal Immunol.* 10.1038/mi.2016.4. [PubMed](#)
276. Seeling M, *et al.* 2013. *Proc Natl Acad Sci U S A.* 110:10729. [PubMed](#)
277. Willemze RA, *et al.* 2019. *Mol Med.* 25:01:00. [PubMed](#)
278. Fransén Pettersson N, *et al.* 2018. *PLoS One.* 13:e0203228. [PubMed](#)
279. Winter C, *et al.* 2018. *Cell Metab.* 28:175. [PubMed](#)
280. Chryplewicz A, *et al.* 2022. *Cancer Cell.* 40:1111. [PubMed](#)
281. Peng V, *et al.* 2022. *Nat Immunol.* 23:619. [PubMed](#)
282. Wang Y, *et al.* 2022. *Nat Commun.* 13:1454. [PubMed](#)
283. Lau P, *et al.* 2022. *Cell Mol Immunol.* .: [PubMed](#)
284. Zhang X, *et al.* 2022. *J Exp Clin Cancer Res.* 41:246. [PubMed](#)
285. Guan D, *et al.* 2021. *Cell Death Dis.* 12:431. [PubMed](#)
286. Chen YL, *et al.* 2022. *Front Neurosci.* 16:876582. [PubMed](#)
287. Xiao Z, *et al.* 2022. *Mater Today Bio.* 15:100297. [PubMed](#)
288. Wang J, *et al.* 2021. *Am J Cancer Res.* 11:2005. [PubMed](#)
289. Wang X, *et al.* 2021. *Theranostics.* 11:209. [PubMed](#)
290. Lux A, *et al.* 2014. *Cell Rep.* 10:236. [PubMed](#)
291. Madsen P, *et al.* 2016. *J Neurosci.* 36: 5128 - 5143. [PubMed](#)
292. Fox B, *et al.* 2016. *PLoS One.* 12: 1006189. [PubMed](#)
293. Parker K, Horn L, Ostrand-Rosenberg S 2016. *J Leukoc Biol.* 100: 463 - 470.. [PubMed](#)
294. Chen MB, *et al.* 2020. *Cell Rep.* 30:4418. [PubMed](#)
295. Dinh HQ, *et al.* 2020. *Immunity.* 53(2):319-334.e6. [PubMed](#)
296. Wang J, *et al.* 2020. *Cell.* 183(7):1867-1883.e26. [PubMed](#)
297. Petriello MC, *et al.* 2018. *Toxicol Sci.* 162:548. [PubMed](#)
298. Severe N *et al.* 2019. *Cell Stem Cell.* 25(4):570-583 . [PubMed](#)
299. Ioanna E Galani *et al.* 2017. *Immunity.* 46(5):875-890 . [PubMed](#)
300. Forte E, *et al.* 2020. *Cell Rep.* 30:3149. [PubMed](#)
301. Wang J, *et al.* 2020. *J Hematol Oncol.* 0.610416667. [PubMed](#)
302. Lai NY, *et al.* 2020. *Cell.* 180:33:00. [PubMed](#)
303. Cong L, *et al.* 2021. *Breast Cancer Res.* 23:51. [PubMed](#)
304. De Micheli AJ, *et al.* 2020. *Am J Physiol Cell Physiol.* 319:C885. [PubMed](#)
305. Sibling E, *et al.* 2021. *Cells.* 10:. [PubMed](#)
306. Oladiran O, *et al.* 2021. *Front Immunol.* 12:720733. [PubMed](#)
307. Schäfer AL, *et al.* 2021. *Front Immunol.* 12:696810. [PubMed](#)
308. Sebastian A, *et al.* 2021. *Cells.* 10:. [PubMed](#)
309. Kerdidani D, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
310. Parent AV, *et al.* 2021. *Cell Reports.* 36(7):109538. [PubMed](#)
311. Ito Y, *et al.* 2021. *Cell Reports.* 35(4):109052. [PubMed](#)

312. Ma Y, *et al.* 2021. *Developmental Cell*. 56(4):478-493.e11. [PubMed](#)  
 313. Ye Y, *et al.* 2020. *Genome Med*. 0.557638889. [PubMed](#)  
 314. Campisi L, *et al.* 2016. *Nat Immunol*. 10.1038/ni.3512. [PubMed](#)  
 315. Holzapfel B, *et al.* 2015. *Biomaterials*. 61: 103-114. [PubMed](#)  
 316. Deniset JF *et al.* 2019. *Immunity*. 51(1):131-140. [PubMed](#)  
 317. Tong Y, *et al.* 2018. *EBioMedicine*. 39:132. [PubMed](#)  
 318. Lee S, *et al.* 2021. *Autophagy*. Online ahead of print. [PubMed](#)  
 319. Swanson WB, *et al.* 2021. *Biomaterials*. 272:120769. [PubMed](#)  
 320. Hofsfield LA, *et al.* 2021. *Elife*. 10:. [PubMed](#)  
 321. Sun D, *et al.* 2020. *PLoS Pathog*. 16:e1008361. [PubMed](#)  
 322. Zhu Q, *et al.* 2021. *J Am Heart Assoc*. 10:e023491. [PubMed](#)  
 323. Amend A, *et al.* 2021. *Int J Mol Sci*. 22:. [PubMed](#)

**RRID** AB\_312980 (BioLegend Cat. No. 103115)  
 AB\_312981 (BioLegend Cat. No. 103116)

## Antigen Details

<b>Structure</b>	Protein tyrosine phosphatase (PTP) family, 180-240 kD
<b>Distribution</b>	All hematopoietic cells except mature erythrocytes and platelets
<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
<b>Cell Type</b>	B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li> <li>2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.</li> <li>3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.</li> <li>4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.</li> </ol>
<b>Gene ID</b>	<a href="#">19264</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse CD45, Biotin anti-mouse CD45, FITC anti-mouse CD45, PE anti-mouse CD45, PE/Cyanine5 anti-mouse CD45, Purified anti-mouse CD45, PE/Cyanine7 anti-mouse CD45, APC/Cyanine7 anti-mouse CD45, Alexa Fluor® 488 anti-mouse CD45, Alexa Fluor® 647 anti-mouse CD45, Pacific Blue™ anti-mouse CD45, Alexa Fluor® 700 anti-mouse CD45, PerCP/Cyanine5.5 anti-mouse CD45, PerCP anti-mouse CD45, Alexa Fluor® 594 anti-mouse CD45, Brilliant Violet 421™ anti-mouse CD45, Brilliant Violet 570™ anti-mouse CD45, Brilliant Violet 510™ anti-mouse CD45, Brilliant Violet 605™ anti-mouse CD45, Purified anti-mouse CD45 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45, Brilliant Violet 711™ anti-mouse CD45, Brilliant Violet 785™ anti-mouse CD45, Brilliant Violet 650™ anti-mouse CD45, APC/Fire™ 750 anti-mouse CD45, Brilliant Violet 750™ anti-mouse CD45, TotalSeq™-A0096 anti-mouse CD45, TotalSeq™-B0096 anti-mouse CD45, Ultra-LEAF™ Purified anti-mouse CD45, Spark Blue™ 550 anti-mouse CD45, Spark NIR™ 685 anti-mouse CD45, TotalSeq™-C0096 anti-mouse CD45, Spark YG™ 570 anti-mouse CD45, PE/Fire™ 640 anti-mouse CD45, APC/Fire™ 810 anti-mouse CD45, PE/Fire™ 700 anti-mouse CD45, Spark Violet™ 538 anti-mouse CD45, Spark YG™ 593 anti-mouse CD45, Spark Blue™ 574 anti-mouse CD45 Antibody

## Product Data



C57BL/6 splenocytes were stained with CD45 (clone 30-F11) APC/Cyanine7 (filled histogram) or Rat IgG2b, ? APC/Cyanine7 isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587